EUVIMEDEUVIMED entdecken
Crossref

Nipocalimab (Imaavy) for Myasthenia Gravis

The Medical Letter on Drugs and Therapeutics · 11.05.2026 · 68 (1754) · e81-e83

DOI: 10.58347/tml.2026.1754g ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Medical Letter on Drugs and Therapeutics, online erschienen am 11.05.2026.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The FDA has approved the neonatal Fc receptor (FcRn) blocker nipocalimab (Imaavy – Janssen) for IV treatment of generalized myasthenia gravis (gMG) in patients ≥12 years old with anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibodies. The FcRn blocker rozanolixizumab (Rystiggo) was approved earlier for the same indication.

Schlagwörter

Stichwörter der Autor:innen

ImaavyRituxanRystiggoSolirisUltomirisVyvgartZilbrysqadverse effectscorticosteroidsdosagedrug interactionseculizumabefficacyefgartigimod alfalactation

Zitieren

APA

(2026). Nipocalimab (Imaavy) for Myasthenia Gravis. The Medical Letter on Drugs and Therapeutics, 68(1754), e81-e83. https://doi.org/10.58347/tml.2026.1754g

Vancouver

Nipocalimab (Imaavy) for Myasthenia Gravis. The Medical Letter on Drugs and Therapeutics. 2026;68(1754):e81-e83. doi:10.58347/tml.2026.1754g

BibTeX
@article{euvimed2026,
  title = {Nipocalimab (Imaavy) for Myasthenia Gravis},
  journal = {The Medical Letter on Drugs and Therapeutics},
  year = {2026},
  volume = {68},
  number = {1754},
  pages = {e81--e83},
  doi = {10.58347/tml.2026.1754g}
}
Kostenlos starten →